SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib un
Related Questions
What are the potential risks or setbacks mentioned in the business update that could affect the stock?
What is the sentiment of institutional investors and analyst rating changes following this announcement?
Are there any upcoming catalyst events (e.g., conference presentations, data releases) that could move the stock in the short term?
What were the key drivers behind any revenue growth or decline reported in the second quarter?
How did the valuation multiples (e.g., P/E, EV/EBITDA) change after the earnings release?
What is the current market share outlook for seralutinib versus other PAH/PH-ILD therapies in development?
How did the company's cash position and runway change after the quarter, and is additional financing required?
How did Gossamer Bio's Q2 2025 revenues and earnings compare to analyst expectations and consensus estimates?
Did Gossamer update the timeline for FDA approval or any regulatory milestones for seralutinib?
Did Gossamer provide guidance for Q3 and full‑year 2025 earnings, and how does it compare with consensus forecasts?
Did the company announce any new partnership or licensing agreements besides the existing Chiesi collaboration?
What are the latest enrollment numbers and data readouts from the seralutinib Phase 2/3 clinical trials?